Aspira Women's Health Files Q1 2025 10-Q

Ticker: AWHL · Form: 10-Q · Filed: May 19, 2025 · CIK: 926617

Sentiment: neutral

Topics: 10-Q, financials, diagnostics

TL;DR

Aspira Women's Health filed its Q1 2025 10-Q. Financials and operations update.

AI Summary

Aspira Women's Health Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Vermillion, Inc., is involved in in vitro & in vivo diagnostic substances. Its principal executive offices are located in Austin, Texas.

Why It Matters

This filing provides an update on Aspira Women's Health's financial performance and operational status for the first quarter of 2025, crucial for investors tracking the company's progress in the diagnostics sector.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new information presented.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Aspira Women's Health Inc.?

Aspira Women's Health Inc. is involved in in vitro & in vivo diagnostic substances, as indicated by its Standard Industrial Classification code.

When was the current 10-Q filing submitted to the SEC?

The 10-Q filing was submitted on May 19, 2025.

What is the fiscal year end for Aspira Women's Health Inc.?

The company's fiscal year ends on December 31.

What were the previous names of Aspira Women's Health Inc.?

Aspira Women's Health Inc. was formerly known as VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC, and ABIOTIC SYSTEMS.

Where are Aspira Women's Health Inc.'s principal executive offices located?

The company's principal executive offices are located at 12117 Bee Caves Road, Building Three, Suite 100, Austin, TX 78738.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 19, 2025 regarding Aspira Women's Health Inc. (AWHL).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing